Suscribirse

Provider Attitudes and Practices Regarding Intrauterine System (IUS) Insertion in Adolescents With and Without Bleeding Disorders for Management of Heavy Menstrual Bleeding - 08/07/21

Doi : 10.1016/j.jpag.2021.01.014 
Katherine L. O'Flynn O'Brien 1, , Allison P. Wheeler 2, Claudia Borzutzky 3, Kristina M. Haley 4, Peter Kouides 5, Oluyemisi Adeyemi-Fowode 6
1 Department of Pediatric and Adolescent Gynecology, Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota 
2 Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 
3 Division of Adolescent and Young Adult Medicine, Children's Hospital Los Angeles/Keck School of Medicine of University of Southern California, Los Angeles, California 
4 Division of Hematology and Oncology, Oregon Health and Science University, Portland, Oregon 
5 Mary M. Gooley Hemophilia Treatment Center, Rochester Regional Health, Rochester, New York 
6 Division of Pediatric and Adolescent Gynecology, Texas Children's Hospital, Houston, Texas 

Address correspondence to: Katherine L. O'Flynn O'Brien, MD, 2530 Chicago Ave S, Suite 390, Minneapolis, MN 55404. Phone: (651) 220-5999; fax: (612) 813-6151.2530 Chicago Ave S, Suite 390MinneapolisMN55404

ABSTRACT

Study Objective

Heavy menstrual bleeding (HMB) may be the sentinel event for identifying a patient with a bleeding disorder (BD). The levonorgestrel intrauterine system (LNG IUS) has been proposed as a treatment for HMB in adolescents with and without BDs; however, no standard protocols for LNG IUS insertion in these populations exist. Providers were surveyed regarding the use of the LNG IUS in adolescents with HMB, with and without BD.

Design, Setting, Participants, Interventions, and Main Outcome Measures

An institutional review board−approved survey assessing provider attitudes, LNG IUS insertion practices, and patient outcomes in adolescents with HMB, with and without BD, was electronically distributed to 3523 providers in the fields of hematology, adolescent medicine, and obstetrics and gynecology. Descriptive analysis was performed.

Results

A total of 312 respondents across all 3 specialties completed the survey. Nearly 100% of respondents considered the LNG IUS safe and effective treatment for adolescents with HMB, both with and without BD. Additionally, 66% of providers chose LNG IUS as the ideal treatment for HMB in patients with BD. Differences were noted in clinical setting for LNG IUS insertion, peri-procedural medication use, and post-procedure follow-up among specialties. Providers across all specialties reported low complication rates related to IUS insertion and use in both patient groups.

Conclusion

Providers considered the LNG IUS safe and effective treatment for HMB in adolescents with and without a diagnosed BD. Practice patterns regarding LNG IUS insertion in this population vary. Further research is necessary to explore IUS outcomes in adolescent patients with HMB, with and without BD, and to inform evidence-based protocols for LNG IUS insertion.

El texto completo de este artículo está disponible en PDF.

Key Words : Heavy menstrual bleeding, Female adolescents, Progesterone-releasing intrauterine devices, Hemostatic disorders


Esquema


 None of the authors have any potential conflicts of interest to disclose.
 Non-financial support was provided by the Foundation for Women and Girls with Blood Disorders (FWGBD). No sources of funding to disclose.
 This work was published as a virtual poster presentation at the North American Society for Pediatric and Adolescent Gynecology (NASPAG) Annual Meeting, Grapevine, TX, on April 1, 2020 (virtual poster presentation secondary to COVID-19 cancellation of in-person meeting).


© 2021  North American Society for Pediatric and Adolescent Gynecology. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 34 - N° 4

P. 514-521 - août 2021 Regresar al número
Artículo precedente Artículo precedente
  • Facilitators and Barriers to Implementation of Long-Acting Reversible Contraceptive Services for Adolescent Girls and Young Women in Gaborone, Botswana
  • Drisana Henry, Sarah Wood, Neo Moshashane, Kehumile Ramontshonyana, Christina Amutah, Pegah Maleki, Claire Howlett, Merrian J. Brooks, Aamirah Mussa, Dipesalema Joel, Andrew P. Steenhoff, Aletha Y. Akers, Chelsea Morroni
| Artículo siguiente Artículo siguiente
  • A Pilot Study to Understand the Adolescent Pain Experience During Contraceptive Implant Insertion
  • S.D. Bentsianov, K. Brandi, P. Chen, N. Shimoni

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.